204 related articles for article (PubMed ID: 21724375)
21. Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
Andaloussi M; Henriksson LM; Więckowska A; Lindh M; Björkelid C; Larsson AM; Suresh S; Iyer H; Srinivasa BR; Bergfors T; Unge T; Mowbray SL; Larhed M; Jones TA; Karlén A
J Med Chem; 2011 Jul; 54(14):4964-76. PubMed ID: 21678907
[TBL] [Abstract][Full Text] [Related]
22. Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.
Narayanaswamy VP; Giatpaiboon S; Baker SM; Wiesmann WP; LiPuma JJ; Townsend SM
PLoS One; 2017; 12(6):e0179776. PubMed ID: 28662114
[TBL] [Abstract][Full Text] [Related]
23. IL-8 released from human lung epithelial cells induced by cystic fibrosis pathogens Burkholderia cepacia complex affects the growth and intracellular survival of bacteria.
Kaza SK; McClean S; Callaghan M
Int J Med Microbiol; 2011 Jan; 301(1):26-33. PubMed ID: 20829108
[TBL] [Abstract][Full Text] [Related]
24. Emerging cystic fibrosis pathogens: incidence and antimicrobial resistance.
Magni A; Giordano A; Mancini C; Pecoraro C; Varesi P; Quattrucci S; Trancassini M
New Microbiol; 2007 Jan; 30(1):59-62. PubMed ID: 17319602
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L
Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942
[TBL] [Abstract][Full Text] [Related]
26. Antibacterial activity of fosmidomycin on chromosomic and plasmid-determined fosfomycin-resistant strains.
Mendez FJ; Alvarez AA; Mendoza MC; Hardisson C
Chemioterapia; 1985 Apr; 4(2):170-5. PubMed ID: 4006006
[TBL] [Abstract][Full Text] [Related]
27. Preliminary data on antibacterial activity of Echinacea purpurea-associated bacterial communities against Burkholderia cepacia complex strains, opportunistic pathogens of Cystic Fibrosis patients.
Chiellini C; Maida I; Maggini V; Bosi E; Mocali S; Emiliani G; Perrin E; Firenzuoli F; Mengoni A; Fani R
Microbiol Res; 2017 Mar; 196():34-43. PubMed ID: 28164789
[TBL] [Abstract][Full Text] [Related]
28. Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species.
Leitão JH; Sousa SA; Ferreira AS; Ramos CG; Silva IN; Moreira LM
Appl Microbiol Biotechnol; 2010 Jun; 87(1):31-40. PubMed ID: 20390415
[TBL] [Abstract][Full Text] [Related]
29. Burkholderia cepacia complex infections: More complex than the bacterium name suggest.
Sfeir MM
J Infect; 2018 Sep; 77(3):166-170. PubMed ID: 30012345
[TBL] [Abstract][Full Text] [Related]
30. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling.
Zhang B; Watts KM; Hodge D; Kemp LM; Hunstad DA; Hicks LM; Odom AR
Biochemistry; 2011 May; 50(17):3570-7. PubMed ID: 21438569
[TBL] [Abstract][Full Text] [Related]
31. Molecular epidemiology of malaria in Cameroon. XXV. In vitro activity of fosmidomycin and its derivatives against fresh clinical isolates of Plasmodium falciparum and sequence analysis of 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
Tahar R; Basco LK
Am J Trop Med Hyg; 2007 Aug; 77(2):214-20. PubMed ID: 17690389
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors.
Devreux V; Wiesner J; Jomaa H; Van der Eycken J; Van Calenbergh S
Bioorg Med Chem Lett; 2007 Sep; 17(17):4920-3. PubMed ID: 17583502
[TBL] [Abstract][Full Text] [Related]
33. Virulence of Burkholderia cepacia complex strains in gp91phox-/- mice.
Sousa SA; Ulrich M; Bragonzi A; Burke M; Worlitzsch D; Leitão JH; Meisner C; Eberl L; Sá-Correia I; Döring G
Cell Microbiol; 2007 Dec; 9(12):2817-25. PubMed ID: 17627623
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.
Peeters E; Nelis HJ; Coenye T
J Antimicrob Chemother; 2009 Oct; 64(4):801-9. PubMed ID: 19633000
[TBL] [Abstract][Full Text] [Related]
35. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion.
Lynch JP
Semin Respir Crit Care Med; 2009 Oct; 30(5):596-610. PubMed ID: 19760547
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the volatile profile of Antarctic bacteria by using solid-phase microextraction-gas chromatography-mass spectrometry.
Romoli R; Papaleo MC; de Pascale D; Tutino ML; Michaud L; LoGiudice A; Fani R; Bartolucci G
J Mass Spectrom; 2011 Oct; 46(10):1051-9. PubMed ID: 22012672
[TBL] [Abstract][Full Text] [Related]
37. Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues.
Ortmann R; Wiesner J; Silber K; Klebe G; Jomaa H; Schlitzer M
Arch Pharm (Weinheim); 2007 Sep; 340(9):483-90. PubMed ID: 17806130
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
Haemers T; Wiesner J; Van Poecke S; Goeman J; Henschker D; Beck E; Jomaa H; Van Calenbergh S
Bioorg Med Chem Lett; 2006 Apr; 16(7):1888-91. PubMed ID: 16439126
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of fosmidomycin analogs as inhibitors of the Synechocystis sp. PCC6803 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
Woo YH; Fernandes RP; Proteau PJ
Bioorg Med Chem; 2006 Apr; 14(7):2375-85. PubMed ID: 16310360
[TBL] [Abstract][Full Text] [Related]
40. Intrinsic Resistance of Burkholderia cepacia Complex to Benzalkonium Chloride.
Ahn Y; Kim JM; Kweon O; Kim SJ; Jones RC; Woodling K; Gamboa da Costa G; LiPuma JJ; Hussong D; Marasa BS; Cerniglia CE
mBio; 2016 Nov; 7(6):. PubMed ID: 27879334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
